In addition, the team discovered that plasma total tau—not just the modified pTau217 form—was elevated in newborns. This is ...

Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...

Alzheimer’s disease is characterized by certain key changes in the brain. Among them are the development of two kinds of ...

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Analysis shows statistically significant survival benefit in individuals with infantile-onset Niemann-Pick disease type C (NPC) treated with adrabetadex compared to matched external controlsFindings ...

Understanding how interactions between the central nervous system and the immune system contribute to problems of aging, ...

Can you escape your genetic inheritance, and do lifestyle changes actually make a difference? Daniel Cossins set out to ...

Results of a systematic review showed that cognitive impairment and neuropsychiatric manifestations are common among patients with various forms of vasculitis.